Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
about
The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481].Lung cancer in elderly patientsPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Lower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung CancerIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineThe Society of Thoracic Surgeons Lung Cancer Resection Risk Model: Higher Quality Data and Superior Outcomes.The role of receipt and timeliness of treatment in socioeconomic inequalities in lung cancer survival: population-based, data-linkage study.Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.Phase angle for prognostication of survival in patients with advanced cancer: preliminary findings.Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial.Cervical squamous cell carcinoma with isolated tibial metastasis: A case report and review of the literature.Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.External validation of the Bayesian Estimated Tools for Survival (BETS) models in patients with surgically treated skeletal metastases.Using claims-based measures to predict performance status score in patients with lung cancerFunctional status declines among cancer survivors: trajectory and contributing factors.A Near-Complete Response to Treatment with Gemcitabine plus nab (®)-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report.Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluationSarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumorsScreening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments.Estimation of an optimal chemotherapy utilisation rate for upper gastrointestinal cancers: setting an evidence-based benchmark for the best-quality cancer careA pure microcytic bladder carcinoma synchronous to prostatic adenocarcinoma.Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model.Lung cancer patients and their spouses: psychological and relationship functioning within 1 month of treatment initiationAssociation of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.A gradient-boosted model analysis of the impact of body mass index on the short-term outcomes of critically ill medical patientsTo Operate or Not: Prediction of 3-Month Postoperative Mortality in Geriatric Cancer Patients.Daily burdens of recipients and family caregivers after lung transplantEfficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study.Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review.Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis.The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients.Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study GroupComparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma.Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases.Predictive Factors for Severe Outcomes in Ischemic Colitis.Cancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches.
P2860
Q24815221-28CC4C84-396F-4FA3-B2BC-01E376D63BACQ28067234-DBBC00F4-78B2-443D-B742-6B2ECCC183CFQ28081243-42062E4D-F3B7-4D37-917B-A73683B72039Q28394473-4AC54326-B014-41AF-AC49-836B4D699956Q29616728-65E786B9-6DA2-4EEC-A081-D233F368D4E7Q30276761-1F36B18E-07A9-4D6D-A4F1-D67D7C64B18CQ30830775-B06EDC4A-9492-4FCF-885D-B7949273291FQ33421926-5503D8C3-B28C-4451-80C2-B11707EEAD2EQ33429761-BC152ADB-97D0-44F2-9BF2-C47FD1892D48Q33706132-29D3FE17-30B4-4D7C-B492-31EC275E19FAQ33762423-A84CADCC-BE0B-4AD6-932A-2B67C207DDAAQ33838556-C285FA2F-00CE-46F9-93D8-8D32B907C7FAQ33845387-C480D2BE-204B-4024-B3E7-6C45D06A8067Q33988445-F1799252-AC91-4870-AF5A-9B84D92EE8BFQ34427331-77172B31-8BF9-4182-B451-F3C6486D826AQ34446810-403EC38B-33D6-4A1B-95DF-1B757CC13A60Q34457923-FAA831A1-7E06-40CD-9C6E-79C0DC4D20A4Q34609460-F03405E4-7CF1-491B-A1A8-26233A2E7387Q34623432-A7773A8C-41B6-48B5-A1A0-24F8588529EDQ34632760-D932E4C8-B6B1-4F43-83C0-38C49C1523A1Q34840438-F764E095-57C6-4981-9B2E-3C7DDD76B6FDQ35096126-2513EC4C-4200-4E09-BF81-50FD583A9214Q35214123-AD0987EB-A60E-4588-AABC-443B9790FBB3Q35344701-3F5B31C7-6376-456B-B46B-B7F27D45E067Q35526843-40635EE1-A58E-4237-ACAA-36EF2657988AQ35659563-560A9ECF-04AF-44E4-93F8-B8D1881D2391Q35680047-8F2A37A4-0CC7-47C2-A818-74DA1CA058B0Q35708619-24B6292A-F25F-45B5-B273-3ACA2F348D04Q35811372-6384CBA2-25F1-45B3-B0C3-4EAE0B71AE42Q35882973-1870ACB4-5FC2-4859-BDC2-6F52E9364039Q35902771-10BDB76A-A057-4B26-A97D-1C555CCDB169Q35914046-EE3EFAFB-DB17-4281-9520-C73EC36BA4C3Q36019483-404B73EB-617E-446C-AC46-63FF92F472A7Q36076614-F71A9C21-7F77-4471-8CAF-EA70C6B6DCD4Q36090012-8B33AA18-C0B5-4630-A195-CCBEB8E73510Q36117206-3A509422-F06D-480C-B6F2-13C473DFC65CQ36160955-8E7737C1-6B7D-4D4A-B39E-75986C799035Q36194180-49B60D8C-0C18-4977-BB8E-C606816E209BQ36223427-27E61CC8-7F38-433B-8D8B-09C6B575B14AQ36333403-1F88BE24-C22D-457F-B661-4254492B6E50
P2860
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Karnofsky and ECOG performance ...... nts from a single institution.
@ast
Karnofsky and ECOG performance ...... nts from a single institution.
@en
Karnofsky and ECOG performance ...... nts from a single institution.
@nl
type
label
Karnofsky and ECOG performance ...... nts from a single institution.
@ast
Karnofsky and ECOG performance ...... nts from a single institution.
@en
Karnofsky and ECOG performance ...... nts from a single institution.
@nl
prefLabel
Karnofsky and ECOG performance ...... nts from a single institution.
@ast
Karnofsky and ECOG performance ...... nts from a single institution.
@en
Karnofsky and ECOG performance ...... nts from a single institution.
@nl
P2093
P1476
Karnofsky and ECOG performance ...... nts from a single institution.
@en
P2093
Buccheri G
Ferrigno D
Tamburini M
P304
P356
10.1016/0959-8049(95)00664-8
P577
1996-06-01T00:00:00Z